文献速递血栓与止血

静脉血栓栓塞症可改变风险与心血管合并症的蛋白质组学洞察

Proteomic insights into modifiable risk of venous thromboembolism and cardiovascular comorbidities.
PubMed 文献 · J Thromb Haemost · 2023-11-27

本研究采用两阶段网络孟德尔随机化分析,探索15种可改变因素、1151种血液蛋白与静脉血栓栓塞症(VTE)的关联,发现10种可改变因素-VTE、86种可改变因素-蛋白及34种蛋白-VTE关联,其中凝血因子XI介导了肥胖、吸烟和失眠与VTE风险的大部分关联。

要点

  • 凝血因子XI介导了吸烟与VTE关联的40%(95%CI 20%-60%)及失眠与VTE关联的27%(95%CI 5%-49%)。
  • 低密度脂蛋白受体相关蛋白12和凝血因子XI介导了3项肥胖指标与VTE的大部分关联。
  • 5种蛋白与VTE及其心血管合并症相关,许多VTE相关蛋白具有血栓性疾病药物可及性。

核心结论

  • 本研究提示凝血因子XI是可成药靶点,是肥胖、吸烟和失眠与VTE风险关联的重要介导因素。

研究设计与样本

  • 两阶段网络孟德尔随机化分析,使用全基因组荟萃分析数据(包括81 190例VTE病例)探索15种可改变因素、1151种血液蛋白与VTE的关联。
  • 蛋白质数据发现分析纳入35 559名个体,复制分析纳入2项独立研究(分别10 708名和54 219名参与者)。

主要发现

  • 网络孟德尔随机化分析识别出10种可改变因素-VTE、86种可改变因素-蛋白和34种蛋白-VTE关联,这些关联在复制分析中总体一致。
  • 识别出38条在可改变因素-蛋白-VTE通路中直接和间接效应方向一致的路径。
  • 低密度脂蛋白受体相关蛋白12(LRP12:34.3%-58.1%)和凝血因子XI(20.6%-39.6%)介导了3项肥胖指标与VTE的大部分关联。
  • 凝血因子XI介导了吸烟与VTE关联的40%(95%CI 20%-60%)及失眠与VTE关联的27%(95%CI 5%-49%)。
  • 5种蛋白(白细胞介素-6受体亚基α、LRP12、凝血酶原、血管生成素-1和低密度脂蛋白受体相关蛋白4)与VTE及其心血管合并症相关。

关键数值与推荐

  • 肥胖指标与VTE的关联中,LRP12介导比例为34.3%-58.1%,凝血因子XI介导比例为20.6%-39.6%。
  • 吸烟与VTE的关联中,凝血因子XI介导比例为40%(95%CI 20%-60%)。
  • 失眠与VTE的关联中,凝血因子XI介导比例为27%(95%CI 5%-49%)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Venous thromboembolism (VTE) has been associated with several modifiable factors (MFs) and cardiovascular comorbidities. However, the mechanisms are largely unknown. OBJECTIVES: We aimed to decipher proteomic pathways underlying the associations of VTE with MFs and cardiovascular comorbidities. METHODS: A 2-stage network Mendelian randomization analysis was conducted to explore the associations between 15 MFs, 1151 blood proteins, and VTE using data from a genome-wide meta-analysis including 81 190 cases of VTE. We used protein data from 35 559 individuals as the discovery analysis, and from 2 independent studies including 10 708 and 54 219 participants as the replication analyses. Based on the identified proteins, we assessed the druggability and examined the cardiovascular pleiotropy. RESULTS: The network Mendelian randomization analyses identified 10 MF-VTE, 86 MF-protein, and 34 protein-VTE associations. These associations were overall consistent in the replication analyses. Thirty-eight pathways with directionally consistent direct and indirect effects in the MF-protein-VTE pathway were identified. Low-density lipoprotein receptor-related protein 12 (LRP12: 34.3%-58.1%) and coagulation factor (F)XI (20.6%-39.6%) mediated most of the associations between 3 obesity indicators and VTE. Likewise, coagulation FXI mediated most of the smoking-VTE association (40%; 95% CI, 20%-60%) and insomnia-VTE association (27%; 95% CI, 5%-49%). Many VTE-associated proteins were highly druggable for thrombotic conditions. Five proteins (interleukin-6 receptor subunit alpha, LRP12, prothrombin, angiopoietin-1, and low-density lipoprotein receptor-related protein 4) were associated with VTE and its cardiovascular comorbidities. CONCLUSION: This study suggests that coagulation FXI, a druggable target, is an important mediator of the associations of obesity, smoking, and insomnia with VTE risk.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Yuan S, Xu F, Zhang H, et al. Proteomic insights into modifiable risk of venous thromboembolism and cardiovascular comorbidities. J Thromb Haemost. 2023. PMID: 38029854. doi:10.1016/j.jtha.2023.11.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。